Anti-Obesity Drugs

This publication has been discontinued on December 6, 2011.

Below is the updated product.

Introduction

Abstract

This report analyzes the worldwide markets for Anti-Obesity Drugs in Millions of US$. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2005 through 2015. The report profiles 85 companies including many key and niche players worldwide such as Abbott Laboratories, Alizyme Plc, Amylin Pharmaceuticals, Inc., AstraZeneca Plc., F.HOFFMANN-LA ROCHE LTD., GlaxoSmithKline Plc, Sanofi-Aventis SA, SuperGen, Inc., Takeda Pharmaceutical Company Limited, and VIVUS, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. Industry Overview

• Current & Future Analysis
• Factors Influencing the Market
• Obesity - A Global Epidemic
• Table 1: Global Overweight Prevalence (2006): Overweight Population (%) of Select Countries (includes corresponding Graph/Chart)
• Table 2: Abdominal Obesity Prevalence (%) by Region and Sex (includes corresponding Graph/Chart)
• Trends and Issues
• Obesity: An Unmet Medical Need
• Rising Demand for Obesity Therapeutics
• Barriers to Development of Effective Drugs
• New Research Aids in Discovery of Novel Drugs
• Growing Problem of Obesity in Asia Particularly China

2. Competition

• Roche Leads the Race
• Table 3: Leading Brands in the Global Anti-obesity Drugs Market (2007): Percentage Share Breakdown of Revenues for Xenical/orlistat, Reductil/Meridia (sibutramine), Alli, Acomplia and Others (includes corresponding Graph/Chart)
• Competition Grows with Pipeline Drugs
• Current Anti-Obesity Drugs in Pipeline: 2008

3. Obesity - An Introduction

• Diagnosis of Obesity
• BMI Calculation and Classification
• Waist Circumference and BMI
• Causes of Obesity
• Unhealthy Eating Habits
• Environmental and Genetic Factors
• Sedentary Lifestyle
• Alcohol Intake
• Childhood Obesity
• Psychological Factors
• Pregnancy
• Hormonal Disorders
• Drugs
• Aging
• Risks Associated with Obesity

4. Obesity Treatment

• Dietary Therapy
• Exercise Therapy
• Behavior Therapy
• Pharmacotherapy
• Weight Loss Surgery
• Invasive Vis-a-vis Non-invasive Procedures
• A Brief Review of Select Invasive Procedures
• Bariatric Surgery
• Laparoscopic Adjustable Gastric Banding
• Vertical Banded Gastroplasty (VBG)
• Roux-en-Y Gastric Bypass Procedure (RYGB)
• Lap-Band Procedure
• Gastric Band Procedure
• Gastric Bypass Procedure
• Doudenal Switch
• Prescription Drugs Vis-a-vis Non-Prescription Drugs
• Table 4: Obesity Treatment Options and Corresponding Success Rate

5. Anti-Obesity Drugs- An Insight

• Introduction
• Mechanism of Action
• Review of Available Drugs
• Phentermine
• Sibutramine
• Orlistat
• Anti-obesity Drugs, Brands and Mechanism of Action
• Table 5: Global Anti-obesity Prescription Drugs Market (2006): Percentage Share Breakdown of Prescriptions by Physician Practices - Primary Care Physicians (PCP), Internal Medicine, Obsterics/Gynecology, Endocrinology/Diabetes, Psychiatry/Neurology, Cardiology and Others (includes corresponding Graph/Chart)
• Review of Select Drugs Awaiting approval / Under Trials

6. Recent Clinical Trials

• Genaera Initiates First Human Trial of Trodusquemine
• Neurogen Completes First Trial of NGD-4715
• Alizyme Secures USFDA Approval for Cetilistat Trials
• GW Pharma to Start Human Trials of New Anti Obesity Drug
• Epix Completes Phase Ib Trial of PRX - 07034
• 7TM Pharma Starts Phase I/II Trial of TM30339
• Arena Starts Phase III Clinical Trials of Lorcaserin
• Drug Induced Serotonin Could Promote Weight Loss
• Takeda Initiates Phase II Clinical Trials of ALT-962
• Glenmark to Commence Phase I Trial of New Anti-Obesity Drug
• Amylin-Leptin Integrated Therapy to Treat Obesity
• Vivus Completes Phase II Trial of Qnexa
• VERNALIS Starts Phase I trial for Obesity
• 7TM Pharma Completes Phase I/ II Clinical Trials of TM30338
• Manhattan Pharmaceuticals Starts Phase I trial of Oleoyl estrone
• Arena Completes Phase2b Trials of APD356
• Metabolic Accomplishes Phase 2b Trials of AOD9604

7. Product Approvals/Launches

• Sanofi-Aventis Receives Swiss Approval for Acomplia
• Zydus Cadila Introduces Slimona
• Torrent Introduces Rimoslim
• Gencor Introduces Slimaluma
• Orexigen Develops Excalia
• Scripps Research Institute Develops Vaccine for Obesity
• Sanofi-Aventis Receives Approval to Market Obesity Drug in EU
• Sanofi-Aventis Rolls Out Acomplia
• Sanofi Secures Approval for Acomplia in the UK
• Novo Nordisk to Develop Anti-obesity Drug
• Sanofi-Aventis Receives Approval to Market Acomplia in Mexico
• Ind-Swift Introduces Sibuslim-10
• Wellnx Launches NV
• Iron-Tek Introduces Appetite Suppressant
• Yamanouchi and Keio University Discover Target Molecule for Developing Anti-obesity Drug

8. Recent Industry Activity

• Pfizer Halts CP-945, 598 Development
• Shionogi to Acquire Sciele Pharma
• Anthill Inks Agreement with Zafgen
• EMEA Suspends Acomplia
• GlaxoSmithKline to Sell Alli as OTC Drug
• Sanofi-Aventis to Market Acomplia in UK
• Orexigen Receives 4th US Patent for Contrave
• BELLUS Health to Acquire Innodia
• Ore Secures License to Develop Romazarit
• GlaxoSmithKline Receives FDA Approval for Orlistat
• Pfizer Receives Approval for Slentrol
• GlaxoSmithKline Secures Licensing Rights of Orlistat
• Pfizer Collaborates with Bristol-Myers Squibb
• Takeda Collaborates with LG Life Sciences
• Takeda to Acquire Paradigm
• Sanofi-Aventis Secures Reimbursement Status for Acomplia
• AstraZeneca Inks Agreement with Palatin Technologies
• Switzerland Includes Acomplia in Reimbursement List
• Allergan Pockets EndoArt
• Sanofi-Aventis Receives Approval for Acomplia in Brazil
• Biocon Inks MoU with Neopharma
• Aurigene Partners with Forest Laboratories
• Pfizer Licenses Obesity Compounds from Bayer Pharmaceuticals
• Merck Terminates Collaboration with Nastech
• Sanofi-Aventis to Receive Rights for Rimonabant
• UMN Pharma Inks Agreement with Crucell and DSM Biologics
• 7TM Pharma Pockets CareX SA
• BioLineRx Inks Licensing Agreement with Yissum
• Aegis Inks Licensing Agreement with Albany Medical College
• Manhattan' s Obesity Drug Approved for Human Trials
• Chugai Halts Development of Anti-Obesity Agent
• HSG Acquires Polymann
• Orchid Pockets Bexel

9. Focus on Select Players

• Abbott Laboratories (US)
• Alizyme Plc (UK)
• Amylin Pharmaceuticals, Inc. (US)
• AstraZeneca Plc (UK)
• F. HOFFMANN-LA ROCHE LTD. (Switzerland)
  • GlaxoSmithKline Plc (UK)
  • Sanofi-Aventis SA (France)
  • SuperGen, Inc. (USA)
  • Takeda Pharmaceutical Company Limited (Japan)
  • VIVUS, Inc. (US)

10. Global Market Perspective

• Table 6: World Recent Past, Current & Future Market Analysis for Anti-Obesity Drugs by Geographic Region - US, Europe and Rest of World Independently Analyzed with Annual Sales Figures in US$ million for Years 2005 through 2015 (includes corresponding Graph/Chart)
• Table 7: World 10-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2006, 2009 and 2015 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Market Overview
  • Table 8: Leading Product Segments in the US Weight Loss Market (2008E): Percent Share Breakdown of Revenues for Diet Drinks, Health Clubs, Bariatric Surgery, Diet Foods, Artificial Sweeteners, Weight Loss Centers, Medically Supervised Programs, Meal Replacements & Appetite Suppressants, Prescription Drugs, Low Calorie Diet Programs and Others (includes corresponding Graph/Chart)
  • Obesity Catching Them Young
  • New Drugs to Rule the Market
  • 37 States Experience Increase in Adult Obesity Rate
  • Statistical Data
  • Table 9: US Obesity Rate (2007): Prevalence Rate of Leading States
  • Table 10: US Obesity Prevalence Estimates and Forecasts (2006-2020) (includes corresponding Graph/Chart)
  • Table 11: US Overweight Prevalence (1998 & 2002): Breakdown of Adult population by Category - Overweight and Obese
  • Table 12: US Obesity Prevalence (2005-2006): Breakdown of Population (%) by Sex and Age Group (includes corresponding Graph/Chart)
  • Table 13: US Anti-obesity Drugs Market (2006 & 2007): Number of Obese People Treated in Million
  • Reimbursement Scenario
  • Regulatory Environment
  • Insufficient Regulatory and Enforcement Laws
  • Obesity and Related Ailments: Burden on Societal and Economic Cost
  • Competition
  • Table 14: US Anti-obesity Drugs Market (2006 and 2007): Percentage Share Breakdown of Revenues by Brand - Meridia, Xenical and Others (includes corresponding Graph/Chart)
  • Recent Clinical Trials
  • Product Approval/Launches
  • Strategic Corporate Developments
  • Review of Major Players
• B. Market Analytics
  • Table 15: US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2. Europe

• A. Market Analysis
  • Market Overview
  • Lack of Reimbursement: Barrier to Market Growth
  • Statistical Data
  • Table 16: Obesity Prevalence (2007) in Select European Union Countries: Obesity Rates by Gender (includes corresponding Graph/Chart)
  • Table 17: Europe Obesity Prevalence (2007) by Gender and Age Category (in 000s) (includes corresponding Graph/Chart)
  • Overview of Novel Policies Adopted by Select European Countries to Prevent Obesity
• B. Market Analytics
  • Table 18: European Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
  • Table 19: European 10-Year Perspective for Anti-Obesity Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2009 and 2015 (includes corresponding Graph/Chart)

2a. France

• A. Market Analysis
  • Market Overview
  • Changing Lifestyle Alter Health Profile
  • Product Approval/Launches
  • Strategic Corporate Developments
  • Sanofi-Aventis SA - A Key Player
• B. Market Analytics
  • Table 20: French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2b. Germany

• A. Market Analysis
  • Table 21: German Anti-obesity Drugs Market (2005 and 2006): Percentage Share Breakdown of Volume Sales by Leading Brands - Meridia and Xenical and Others
• B. Market Analytics
  • Table 22: German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2c. Italy

• Market Analysis
• Table 23: Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2d. The United Kingdom

• A. Market Analysis
  • Market Overview
  • Table 24: UK Childhood Prevalence (1995-2005): Percentage of Obese Children Aged 2-15 years (includes corresponding Graph/Chart)
  • Recent Clinical Trials
  • Product Approval/Launches
  • Strategic Corporate Developments
  • Review of Major Players
• B. Market Analytics
  • Table 25: UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2e. Rest of Europe

• A. Market Analysis
  • Recent Clinical Trials
  • Product Approval/Launches
  • Strategic Corporate Developments
  • F. HOFFMANN-LA ROCHE LTD. - A Key Player
• B. Market Analytics
  • Table 26: Rest of Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

3. Rest of World

• A. Market Analysis
  • Brief Review of Select Regions
  • Canada
  • Table 27: Canadian Obesity Prevalence (1979 & 2004): Obesity Rate by Age Group (includes corresponding Graph/Chart)
  • Table 28: Canadian Adult Overweight and Obesity Prevalence (2004): Breakdown of Population (in 000s) by Sex
  • Asia-Pacific
  • Australia
  • Table 29: Prevalence Rate (%) of overweight/obese Students in Australia (includes corresponding Graph/Chart)
  • China
  • India
  • Drugs Under Development by Indian Companies
  • Japan
  • Takeda Pharmaceutical Company Limited - A Key Player
  • Korea
  • Use of Diet Pills Lack Proper Monitoring
  • New Zealand
  • Recent Clinical Trials
  • Product Approval/Launches
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 30: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Related Reports